This grant is being offered on behalf of the Susan G. Komen-Inflammatory Breast Cancer Research Foundation IBC Collaborative in partnership with the Milburn Foundation, building on a longstanding collaboration aimed at accelerating IBC research and improving outcomes for people with IBC. This is a limited submission opportunity. Each institution may submit ONE nominee to apply for this funding opportunity. Applicants/PIs cannot self-nominate. 

Although IBC has been recognized as a distinct form of breast cancer for over a century, its etiology and underlying biological mechanisms remain poorly understood. Consequently, no validated, widely adopted IBC-specific biomarkers or targeted therapies exist, and current management is largely informed by evidence from non-IBC breast cancer. This limited understanding of IBC biology remains a significant barrier to the development of more precise diagnostic and therapeutic approaches, highlighting the need for research focused on the unique, biological mechanisms driving the disease. Therefore, the goal of the Inflammatory Breast Cancer (IBC) Research Grant is to support innovative, hypothesis-driven research that advances our understanding of the biological underpinnings of IBC and opens new avenues of investigation into the disease. 

This solicitation seeks translational research project proposals for an upcoming NCI Specialized Program of Research Excellence (SPORE) grant in Thoracic Cancer at Johns Hopkins SKCCC, with a submission date in September 2027. SPORE grants target interdisciplinary translational cancer research and involve both basic and clinical/applied scientists, supporting projects that will result in new approaches to the prevention, early detection, diagnosis, and treatment of human cancers. (PAR-23-284: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required))*